Back to mobile site

Jefferies Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)

June 5, 2025 5:24 AM EDT Send to a Friend
Jefferies analyst Dennis Ding reiterated a Buy rating and $80.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login